Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    12644542 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Condition: Peritoneal Cancer
Interventions: Drug: Sorafenib;   Biological: Bevacizumab;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Procedure: dynamic contract-enhanced magnetic resonance imaging;   Procedure: needle biopsy;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18

Indicates status has not been verified in more than two years